Checkpoint Therapeutics, Inc. (CKPT)

Checkpoint Therapeutics, Inc. is a clinical-stage immunotherapy and targeted oncology company dedicated to developing novel treatments for solid tumor cancers. Their lead product candidate, Cosibelimab, targets the PD-L1 pathway to enhance anti-tumor immune responses.

46/100 AI Score MCap $367.72M Vol 581.5K

Company Overview

CEOJames F. Oliviero III,
Employees24
HeadquartersWaltham, MA, US
IPO Year2016

Checkpoint Therapeutics pioneers innovative cancer therapies, focusing on its lead asset Cosibelimab, a PD-L1 inhibitor, and a diverse pipeline targeting significant unmet needs in solid tumor oncology, offering a compelling investment opportunity in the rapidly evolving immunotherapy landscape with a market cap of $0.37B.

Investment Thesis

Checkpoint Therapeutics presents a compelling investment opportunity due to its focus on innovative cancer immunotherapies and targeted oncology treatments. The lead asset, Cosibelimab, has the potential to capture a significant share of the PD-L1 inhibitor market, with ongoing clinical trials evaluating its efficacy across various solid tumors. The company's pipeline, including CK-302 and Olafertinib, provides additional value drivers by targeting different mechanisms and cancer types. With a market capitalization of $0.37 billion, Checkpoint offers potential upside as it progresses its clinical programs and seeks regulatory approvals. Key catalysts include upcoming clinical trial readouts for Cosibelimab and advancement of its other pipeline assets. The company's strategic collaboration with TG Therapeutics further strengthens its position in the hematological malignancies space.

Key Highlights

  • Market Cap of $0.37B reflects the company's current valuation and potential for growth in the oncology market.
  • Lead product candidate Cosibelimab targets the PD-L1 pathway, a validated target in cancer immunotherapy.
  • Developing Olafertinib, a third-generation EGFR inhibitor, addressing a specific mutation in non-small cell lung cancer.
  • Collaboration agreement with TG Therapeutics, Inc. expands development and commercialization opportunities in hematological malignancies.
  • Beta of 1.14 indicates a slightly higher volatility compared to the market, reflecting the risk associated with clinical-stage biotechnology companies.

Competitors

Strengths

  • Promising lead product candidate, Cosibelimab.
  • Diversified pipeline of oncology assets.
  • Strategic collaboration with TG Therapeutics.
  • Experienced management team.

Weaknesses

  • Clinical-stage company with no approved products.
  • Reliance on successful clinical trial outcomes.
  • Limited financial resources.
  • Competition from larger pharmaceutical companies.

Catalysts

  • Upcoming: Clinical trial data readouts for Cosibelimab in various solid tumors.
  • Upcoming: Advancement of CK-302 into clinical development.
  • Upcoming: Regulatory submissions for Cosibelimab.
  • Ongoing: Expansion of pipeline through strategic acquisitions.
  • Ongoing: Establishment of partnerships with larger pharmaceutical companies.

Risks

  • Potential: Clinical trial failures for its product candidates.
  • Potential: Regulatory setbacks or delays.
  • Ongoing: Competition from other therapies in the market.
  • Ongoing: Dependence on securing additional funding.
  • Ongoing: Market access challenges and pricing pressures.

Growth Opportunities

  • Cosibelimab Clinical Development: Cosibelimab represents a significant growth opportunity as it progresses through clinical trials for various solid tumors. Positive clinical data and potential regulatory approvals could drive substantial revenue growth. The market for PD-L1 inhibitors is estimated to reach billions of dollars, offering a large addressable market for Cosibelimab. Timeline: Ongoing clinical trials with potential data readouts in the next 12-24 months.
  • Olafertinib Development: Olafertinib, a third-generation EGFR inhibitor, targets a specific mutation in non-small cell lung cancer. Successful development and commercialization could capture a portion of the EGFR inhibitor market. The market for EGFR inhibitors is substantial, with ongoing advancements in personalized medicine driving demand. Timeline: Clinical development ongoing with potential for future expansion.
  • CK-302 Development: CK-302, a human agonistic antibody targeting GITR expressing cells, represents a novel approach to cancer immunotherapy. Successful development could lead to a new class of immunotherapies. The market for GITR-targeted therapies is emerging, offering a first-mover advantage for Checkpoint. Timeline: Preclinical and early clinical development with potential for future clinical trials.
  • Expansion of Pipeline: Checkpoint has the opportunity to expand its pipeline through strategic acquisitions and in-licensing of promising oncology assets. This could diversify its portfolio and reduce reliance on its lead product candidates. The market for oncology assets is competitive, but Checkpoint's expertise and strategic approach could enable it to secure valuable assets. Timeline: Ongoing efforts to identify and acquire new assets.
  • Partnerships and Collaborations: Checkpoint can leverage partnerships and collaborations to accelerate the development and commercialization of its products. Collaborations with larger pharmaceutical companies could provide access to resources and expertise. The market for oncology partnerships is active, with ongoing deals between biotechnology and pharmaceutical companies. Timeline: Ongoing efforts to establish strategic partnerships.

Opportunities

  • Positive clinical data for Cosibelimab.
  • Expansion of pipeline through acquisitions.
  • Partnerships with larger pharmaceutical companies.
  • Regulatory approvals for its therapies.

Threats

  • Clinical trial failures.
  • Regulatory setbacks.
  • Competition from other therapies.
  • Market access challenges.

Competitive Advantages

  • Proprietary immunotherapy and targeted therapy assets.
  • Clinical data supporting the efficacy and safety of its product candidates.
  • Strategic collaborations with other companies.
  • Expertise in oncology drug development.

About

Checkpoint Therapeutics, Inc., founded in 2014 and based in Waltham, Massachusetts, is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. As a subsidiary of Fortress Biotech, Inc., Checkpoint leverages a strategic approach to build a diversified portfolio of oncology assets. The company's lead product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1), blocking its interaction with programmed death receptor-1 (PD-1) and B7.1 receptors. This mechanism is designed to enhance anti-tumor immune responses. In addition to Cosibelimab, Checkpoint is developing CK-302, a human agonistic antibody targeting GITR expressing cells, Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor for EGFR mutation-positive non-small cell lung cancer, CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains, and an anti-carbonic anhydrase IX (CAIX) antibody. The company also has a collaboration agreement with TG Therapeutics, Inc. to develop and commercialize certain assets in hematological malignancies. Checkpoint's strategy involves acquiring promising oncology assets and advancing them through clinical development to address unmet needs in cancer treatment.

What They Do

  • Develops immunotherapies for solid tumor cancers.
  • Focuses on acquiring and advancing novel cancer treatments.
  • Creates fully-human monoclonal antibodies like Cosibelimab.
  • Develops targeted therapies for specific cancer mutations.
  • Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
  • Seeks regulatory approvals for its therapies.
  • Commercializes its approved therapies to treat cancer patients.

Business Model

  • Acquires and develops promising oncology assets.
  • Conducts clinical trials to demonstrate efficacy and safety.
  • Seeks regulatory approvals from agencies like the FDA.
  • Commercializes approved therapies directly or through partnerships.

Industry Context

Checkpoint Therapeutics operates within the dynamic and competitive biotechnology industry, specifically focusing on oncology. The market for cancer therapies is substantial and growing, driven by an aging population and advancements in personalized medicine. Immunotherapy, particularly PD-1/PD-L1 inhibitors, has revolutionized cancer treatment, with significant market share. Key competitors include companies developing similar immunotherapies and targeted therapies. Checkpoint's success depends on its ability to differentiate its products, secure regulatory approvals, and effectively commercialize its therapies. Competitors include CLYM, GTHX, INZY, ITOS, and ORTX. The industry is characterized by high R&D costs, regulatory hurdles, and intense competition.

Key Customers

  • Cancer patients with solid tumors.
  • Oncologists and other healthcare professionals.
  • Hospitals and cancer treatment centers.
  • Pharmaceutical companies (potential partners).
AI Confidence: 71% Updated: 2/9/2026

Financials

Chart & Info

Price Chart

Checkpoint Therapeutics, Inc. (CKPT) stock price: $4.28 (+0.00, +0.00%)

Why Bull

  • •Recent insider buying suggests those in the know see value, potentially signaling undervaluation.
  • •The community is buzzing about potential catalysts, indicating strong belief in the company's pipeline.
  • •Positive sentiment around recent trial updates is creating upward momentum in market perception.
  • •The market seems to be responding well to the company's strategic partnerships, indicating confidence in their growth strategy.

Why Bear

  • •Community concerns about cash burn are creating selling pressure, reflecting worries about funding.
  • •Negative sentiment regarding competitor advancements is dampening enthusiasm for Checkpoint's prospects.
  • •Market perception is cautious due to past clinical trial setbacks, creating skepticism.
  • •Recent insider selling, although less prominent than buying, might indicate profit-taking or concerns about future performance.

Latest News

Technical Analysis

RSI(14)
--
MACD
--
Volume
NaN

Rationale

AI-generated technical analysis for CKPT including trend direction, momentum, and pattern recognition.

What to Watch

Key support and resistance levels, volume signals, and upcoming events.

Risk Management

Position sizing, stop-loss levels, and risk-reward assessment.

Community

Discussion

Share your analysis and discuss Checkpoint Therapeutics, Inc. (CKPT) with other investors. Log in to post.

Sentiment

Community sentiment and discussion activity for CKPT.

Make a Prediction

Set your price target for Checkpoint Therapeutics, Inc. (CKPT), choose a timeframe, and track your prediction accuracy.

Current price: $4.28

Analyst Consensus

Consensus Rating

Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CKPT.

Price Targets

Wall Street price target analysis for CKPT.

Insider Flow (30d)

No insider trades in the last 30 days.

MoonshotScore

45.5/100

Score Factors

  • Revenue Growth 5/100

    Revenue growth data is currently unavailable for this company.

  • Gross Margin 5/100

    Gross margin data is currently unavailable for this company.

  • Operating Leverage 4/100

    Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.

  • Cash Runway 5/100

    Cash position data is currently unavailable for this company.

  • R&D Intensity 5/100

    R&D spending data is currently unavailable for this company.

  • Insider Activity 6/100

    No significant insider buying or selling recently, which is neutral for the stock outlook.

  • Short Interest 5/100

    Float and volume data unavailable for liquidity analysis.

  • Price Momentum 0/100

    No bullish technical signals detected. The stock lacks upward price momentum currently.

  • News Sentiment 5/100

    No sentiment data available

What does this score mean?

The MoonshotScore rates CKPT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.

Frequently Asked Questions

What does Checkpoint Therapeutics, Inc. do?

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead product candidate is Cosibelimab, a fully-human monoclonal antibody that targets the PD-L1 pathway to enhance anti-tumor immune responses. Checkpoint also develops other targeted therapies and immunotherapies, aiming to address unmet needs in cancer treatment. Their business model involves acquiring promising oncology assets, conducting clinical trials, and seeking regulatory approvals to bring innovative therapies to market.

Is CKPT stock a good buy?

CKPT stock presents a speculative investment opportunity with potential upside, driven by its promising lead asset, Cosibelimab, and a diversified pipeline. However, as a clinical-stage company, it carries significant risk associated with clinical trial outcomes and regulatory approvals. The company's market capitalization of $0.37 billion reflects its current valuation and potential for growth. Investors should carefully consider the risks and potential rewards before investing in CKPT, taking into account the competitive landscape and the company's financial resources. Positive clinical data and regulatory milestones could drive significant value appreciation.

What are the main risks for CKPT?

The main risks for Checkpoint Therapeutics include clinical trial failures, regulatory setbacks, competition from other therapies, and dependence on securing additional funding. As a clinical-stage company, Checkpoint's success hinges on the positive outcomes of its clinical trials. Negative or inconclusive results could significantly impact the company's valuation. Regulatory approvals are also uncertain and subject to delays. Checkpoint faces competition from larger pharmaceutical companies with greater resources. The company's financial stability depends on its ability to secure additional funding through equity offerings, partnerships, or other means.

Is CKPT a good stock to buy?

Whether CKPT is a good investment depends on your financial goals, risk tolerance, and investment horizon. Key factors to evaluate include the company's revenue growth trajectory, profit margins, debt-to-equity ratio, competitive moat, and valuation multiples (P/E, P/S, EV/EBITDA) relative to industry peers. Our AI-generated Investment Thesis and SWOT analysis on this page provide a data-driven starting point. Always do your own research and consider consulting a financial advisor before making investment decisions.

What is the CKPT MoonshotScore?

The MoonshotScore for CKPT is an AI-powered rating from 0 to 100 that evaluates a stock across four dimensions: growth potential (revenue and earnings trajectory), financial health (balance sheet strength, cash flow), market momentum (price trends, volume patterns, institutional flows), and risk factors (volatility, debt levels, sector headwinds). Scores above 70 indicate strong potential, 50-70 moderate, and below 50 suggests caution. The score is recalculated daily using the latest financial data and market signals.

How often is CKPT data updated?

CKPT stock prices are updated in real-time during U.S. market hours (9:30 AM - 4:00 PM ET, Monday through Friday). After-hours and pre-market prices are also tracked. Company fundamentals (earnings, revenue, balance sheet) are refreshed when new quarterly or annual reports are filed. Analyst ratings, price targets, and AI-generated insights are updated daily. Breaking news related to CKPT is aggregated continuously from premium financial news sources throughout the day.

What are the growth catalysts for CKPT?

Growth catalysts for Checkpoint Therapeutics, Inc. (CKPT) can include several categories: product catalysts (new launches, FDA approvals, patent grants), financial catalysts (earnings beats, margin expansion, share buybacks), strategic catalysts (acquisitions, partnerships, market expansion into new regions), and macro catalysts (favorable regulation, industry tailwinds, secular growth trends). Our AI analyzes Checkpoint Therapeutics, Inc.'s specific catalysts using earnings transcripts, SEC filings, and news sentiment to identify the most impactful near-term and long-term drivers.

Who are CKPT's main competitors?

Checkpoint Therapeutics, Inc. (CKPT) competes with companies in its industry that target similar customers, markets, or product categories. Competitor analysis involves comparing key metrics: market share, revenue growth rates, profit margins, R&D spending, and valuation multiples. Understanding competitive positioning helps investors assess whether CKPT has a sustainable competitive advantage (moat) through brand strength, network effects, cost leadership, or switching costs. Our Competitors section provides a side-by-side comparison with relevant peers.

What do analysts say about CKPT?

Wall Street analyst coverage for CKPT includes consensus ratings (buy, hold, or sell), 12-month price targets, and earnings estimates. Analyst opinions are aggregated from major investment banks and research firms. Key metrics to watch include the consensus price target (average, high, and low estimates), the number of analysts covering the stock, any recent rating changes (upgrades or downgrades), and how actual earnings compare to analyst estimates (beat or miss history). Our platform aggregates these from multiple data providers for a comprehensive view.

What is CKPT's market cap?

Market capitalization (market cap) for CKPT is calculated by multiplying the current share price by the total number of outstanding shares. It represents the market's total valuation of the company. Stocks are typically categorized as mega-cap ($200B+), large-cap ($10B-$200B), mid-cap ($2B-$10B), small-cap ($300M-$2B), or micro-cap (under $300M). Market cap influences index inclusion, institutional ownership eligibility, and risk profile. Our Key Statistics section shows CKPT's current market cap alongside enterprise value and other valuation metrics.

How has CKPT stock performed recently?

CKPT's recent stock performance can be evaluated across multiple timeframes: daily price changes, week-over-week momentum, monthly trends, and year-to-date returns. Important performance indicators include the stock's 52-week high and low, moving averages (50-day and 200-day SMA), relative strength index (RSI), and volume trends. Comparing CKPT's performance against its sector index and the S&P 500 provides context on whether it is outperforming or underperforming the broader market.

What are the risks of investing in CKPT?

Key risk categories for CKPT include: market risk (overall market downturns affecting stock prices), company-specific risk (management changes, product failures, competitive threats), financial risk (high debt levels, cash burn, dilution from stock issuance), regulatory risk (government policy changes, lawsuits, compliance issues), and macroeconomic risk (interest rate changes, inflation, currency fluctuations). Beta measures CKPT's volatility relative to the market - a beta above 1.0 means higher volatility than the S&P 500. Our AI-generated risk assessment identifies the most relevant risk factors for this specific stock.

Are insiders buying or selling CKPT?

Insider trading activity for CKPT tracks purchases and sales by company executives, directors, and major shareholders (10%+ owners) as reported in SEC Form 4 filings. Insider buying is generally considered a bullish signal because insiders have the deepest knowledge of company operations, while selling may have various motivations (diversification, tax planning, pre-planned 10b5-1 trading plans). Key metrics include the buy-to-sell ratio, total dollar value of insider transactions, and whether multiple insiders are trading in the same direction. Our Insider Flow tab shows recent transactions with dates and dollar amounts.

Is CKPT a good stock for beginners?

Checkpoint Therapeutics, Inc. (CKPT) can be suitable for beginner investors depending on several factors. Look at the MoonshotScore on this page for an overall AI-powered assessment of growth potential and risk. Beginners should also check the company's market cap (larger companies tend to be less volatile), gross margin (higher margins mean stronger business fundamentals), and cash position (healthy cash reduces bankruptcy risk). Always start with a small position size and never invest money you cannot afford to lose.

How risky is CKPT for first-time investors?

Every stock carries risk, including Checkpoint Therapeutics, Inc. (CKPT). First-time investors should review the Risk Factors section on this page for company-specific risks. Key risk indicators include price volatility (check the chart for daily swings), insider selling activity (see Insider Flow tab), and cash runway (see MoonshotScore breakdown). A diversified portfolio with an index fund like the S&P 500 as a core holding is generally recommended before adding individual stocks like CKPT.

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Data provided for informational purposes only.

AI Analysis Notes
  • Information is based on available data and may be subject to change.
  • Investment decisions should be based on individual risk tolerance and due diligence.
Data Sources
profilefundamentalsexistingCopy